Crinetics presents phase 2 data for CAH treatment atumelnant

Cevap yazmak için giriş yap yada kayıt ol.
Benzer konular Forum Tarih
A Entera Bio presents Phase 1 data on single-tablet EB613 Hisse Senetleri 0 10
A Upstream Bio presents positive Phase 2 trial data for verekitug Hisse Senetleri 0 4
A Agios presents detailed mitapivat trial results for sickle cell Hisse Senetleri 0 8
A Intellia presents Phase 3 results for HAE gene therapy lonvo-z Hisse Senetleri 0 7
A Disc Medicine presents trial data for blood disorder treatments Hisse Senetleri 0 9
A Crinetics Pharma CFO Schilke sells $266k in stock Hisse Senetleri 0 34
A Crinetics stock price target raised to $80 from $77 at Morgan Stanley Hisse Senetleri 0 29
A Crinetics to host conference call on paltusotine and atumelnant data Hisse Senetleri 0 39

Benzer konular

Üst